Otrivine Anti-Allergie (Fluticasone Propionate)

Otrivine Anti-Allergie is a nasal corticosteroid indicated for conditions affecting the nasal mucosa and allergic response.

• Allergic rhinitis: reduces nasal congestion, itching and sneezing associated with seasonal or perennial allergens.
• Seasonal allergic nasal symptoms: alleviates inflammation and discharge during pollen or mold exposure.
• Perennial allergic rhinitis: provides sustained relief of chronic nasal inflammation caused by indoor allergens such as dust mites.

• Fluticasone propionate binds to intracellular glucocorticoid receptors in nasal mucosal cells, altering gene transcription. This down‑regulates pro‑inflammatory cytokines, chemokines and adhesion molecules, leading to decreased vascular permeability and reduced inflammatory cell infiltration, thereby diminishing nasal mucosal edema and irritation.

Adverse reactions are generally mild to moderate and reflect local or systemic exposure to a corticosteroid.

Common Side Effects

• Nasal irritation or burning sensation.
• Epistaxis (nosebleeds).
• Headache.
• Throat irritation or dryness.
• Cough.
• Unpleasant taste.

Serious or Rare Side Effects

• Nasal septal perforation.
• Secondary fungal infection of the nasal passages.
• Elevated intra‑ocular pressure or glaucoma.
• Systemic corticosteroid effects such as adrenal suppression (rare with recommended use).
• Severe allergic reaction (anaphylaxis).

When using Otrivine Anti-Allergie, consider the following safety measures:

• Assess patient history: verify no recent nasal surgery or trauma.
• Monitor for infection: discontinue if signs of nasal or sinus infection appear.
• Caution in glaucoma: avoid prolonged use in patients with elevated intra‑ocular pressure.
• Pregnancy and lactation: use only if clearly needed after risk‑benefit assessment.
• Pediatric use: follow age‑specific guidelines and avoid excessive dosing.
• Store at ambient temperature: keep below 25°C, protect from moisture and keep in original packaging.

Fluticasone propionate nasal spray has a low potential for systemic drug interactions, but certain agents may modify its safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase systemic exposure.

Moderate Interactions (Monitor Closely)

• Nasal decongestant sprays: concurrent use can increase risk of nasal mucosal irritation.
• Antifungal nasal preparations: may alter local flora and increase infection risk.
• Systemic corticosteroids: additive systemic glucocorticoid effects.
• Antihistamines: may enhance sedative effects when combined with sedating antihistamines.
• Immunosuppressants: monitor for heightened risk of local infection.